
Sun Pharma Switzerland Ltd. Wollerau

ANNUAL REPORT

01.04.2022 - 31.03.2023



Experfina AG, Picassoplatz 8, CH-4052 Basel

DETAILED BALANCE SHEET as at 31. March 2023

| | Foreign currency | | 31.03.2023 CHF | 31.03.2022 CHF | +/- CHF |
|-----------------------------|------------------|-----------|-------------------|-------------------|-------------------|
| ASSETS | | | | | |
| UBS AG, CC CHF | | | 8,456.89 | 17,582.03 | -9,125.14 |
| UBS AG, CC USD | USD | 18.92 | 17.88 | 25.75 | -7.87 |
| UBS AG, CC EUR | EUR | 68,886.99 | 69,329.24 | 12,136.75 | 57,192.49 |
| Cash at bank | | | 77,804.01 | 29,744.53 | 48,059.48 |
| Debtors EUR | EUR | 18,902.42 | 19,024.00 | 27,892.46 | -8,868.46 |
| Debtor VAT | | | 126.22 | 391.00 | -264.78 |
| Debtors | | | 19,150.22 | 28,283.46 | -9,133.24 |
| Prepaid expenses | | | 4,337.70 | 43,651.30 | -39,313.60 |
| Accrued revenues | | | 4,337.70 | 43,651.30 | -39,313.60 |
| TOTAL CURRENT ASSETS | | | 101,291.93 | 101,679.29 | -387.36 |
| TOTAL ASSETS | | | 101,291.93 | 101,679.29 | -387.36 |

DETAILED BALANCE SHEET as at 31. March 2023

| | Foreign currency | 31.03.2023 CHF | 31.03.2022 CHF | +/- CHF |
|----------------------------------|------------------|-------------------|-------------------|------------------|
| LIABILITIES | | | | |
| Creditor AHV/ALV/FAK | | 4,783.75 | 0.00 | 4,783.75 |
| Creditor pension fund | | 4,702.70 | 100.70 | 4,602.00 |
| Creditor accident insurance | | 330.60 | 0.00 | 330.60 |
| Creditor disability insurance | | 718.15 | 0.00 | 718.15 |
| Withholding Tax | | 5,869.80 | 0.00 | 5,869.80 |
| Creditors | | 16,405.00 | 100.70 | 16,304.30 |
| Accrued liabilities | | 20,747.00 | 22,940.00 | -2,193.00 |
| Accrued liabilities | | 20,747.00 | 22,940.00 | -2,193.00 |
| TOTAL CURRENT LIABILITIES | | 37,152.00 | 23,040.70 | 14,111.30 |

DETAILED BALANCE SHEET as at 31. March 2023

| | Foreign currency | 31.03.2023 CHF | 31.03.2022 CHF | +/- CHF |
|-----------------------------------|------------------|-------------------|-------------------|-------------------|
| Share capital | | 100,000.00 | 100,000.00 | 0.00 |
| Share Capital | | 100,000.00 | 100,000.00 | 0.00 |
| Legal reserves | | 2,100.00 | 2,100.00 | 0.00 |
| Legale reserve | | 2,100.00 | 2,100.00 | 0.00 |
| Loss brought forward | | -23,461.41 | 9,272.18 | -32,733.59 |
| Loss of the period | | -14,498.66 | -32,733.59 | 18,234.93 |
| Loss | | -37,960.07 | -23,461.41 | -14,498.66 |
| TOTAL SHAREHOLDER'S EQUITY | | 64,139.93 | 78,638.59 | -14,498.66 |
| TOTAL LIABILITIES | | 101,291.93 | 101,679.29 | -387.36 |

DETAILED PROFIT AND LOSS ACCOUNT from 1. April 2022 till 31. March 2023

| | 2022 - 2023 CHF | 2021 - 2022 CHF | +/- CHF |
|--------------------------------|--------------------|--------------------|-------------------|
| Revenues intra group | 581,292.77 | 627,283.81 | -45,991.04 |
| Income for Services | 581,292.77 | 627,283.81 | -45,991.04 |
| Total Operating income | 581,292.77 | 627,283.81 | -45,991.04 |
| Phone, Internet, IT | -2,788.63 | -2,664.49 | -124.14 |
| Management fees | -21,391.25 | -21,281.25 | -110.00 |
| Administration fees | -5,714.21 | -5,675.00 | -39.21 |
| Audit | 0.00 | -3,675.00 | 3,675.00 |
| Registration fees | -10,755.70 | -272,081.62 | 261,325.92 |
| Public liability insurance | -309.45 | -309.85 | 0.40 |
| Other fees and charges | -120.00 | -356.45 | 236.45 |
| Legal fees | -1,857.00 | -10,028.36 | 8,171.36 |
| Administrative expenses | -42,936.24 | -316,072.02 | 273,135.78 |
| Operating Result 1 | 538,356.53 | 311,211.79 | 227,144.74 |

DETAILED PROFIT AND LOSS ACCOUNT from 1. April 2022 till 31. March 2023

| | 2022 - 2023 CHF | 2021 - 2022 CHF | +/- CHF |
|--|--------------------|--------------------|--------------------|
| Gross salary | -426,670.25 | -266,664.00 | -160,006.25 |
| Refund of accident and daily sickness allowance | 0.00 | 324.80 | -324.80 |
| AHV/ALV | -32,703.80 | -20,244.55 | -12,459.25 |
| Pension fund | -39,427.25 | -28,414.15 | -11,013.10 |
| Accident insurance | -3,335.85 | -2,157.15 | -1,178.70 |
| Disability insurance | -4,165.65 | -2,849.80 | -1,315.85 |
| Travel fees effective | -28,580.90 | -4,197.85 | -24,383.05 |
| Personal costs | -534,883.70 | -324,202.70 | -210,681.00 |
| Debit interest | -0.05 | 0.00 | -0.05 |
| Bank charges | -432.89 | -368.41 | -64.48 |
| Exchange differences | -16,785.80 | -19,137.52 | 2,351.72 |
| Financial expenses | -17,218.74 | -19,505.93 | 2,287.19 |
| Financial result | -17,218.74 | -19,505.93 | 2,287.19 |
| Operating result 2 | -13,745.91 | -32,496.84 | 18,750.93 |
| Extraordinary Revenue | -500.00 | 0.00 | -500.00 |
| Extraordinary revenue | -500.00 | 0.00 | -500.00 |
| Extraordinary revenue | -500.00 | 0.00 | -500.00 |

DETAILED PROFIT AND LOSS ACCOUNT from 1. April 2022 till 31. March 2023

| | 2022 - 2023 CHF | 2021 - 2022 CHF | +/- CHF |
|---------------------------------|--------------------|--------------------|---------------|
| Operating profit (before taxes) | -14,245.91 | -32,496.84 | 18,250.93 |
| Taxes | -252.75 | -236.75 | -16.00 |
| Taxes | -252.75 | -236.75 | -16.00 |
| Loss of the period | -14,498.66 | -32,733.59 | 18,234.93 |

Sun Pharma Switzerland Ltd., Wollerau

Notes to the annual report as of 31. March 2023

1. Principles

1.1 General aspects

These financial statements were prepared according to the provisions of the Swiss Law on Accounting and Financial Reporting (32nd title of the Swiss code of Obligations). Where not prescribed by law, the significant accounting and valuation principles applied are described below. It should be noted that to ensure the company's going concern, the company's financial statements may be influenced by the creation and release of hidden reserves.

2. Information on balance sheet and income statement items

none

3. Other Informations

3.1 Full-time equivalents

The full-time equivalents were below 10.

3.2 Extraordinary expenses

In the profit and loss account is no extraordinary position in the current financial year.

3.3 Significant occurrence after the balance sheet date

There are no significant occurrence after the balance sheet date, which could impact the book value of the assets or liabilities or which should be disclosed here.

Sun Pharma Switzerland Ltd., Wollerau

Notes to the annual report as of 31. March 2023

4. Proposed Appropriation of retained earnings for the financial year 2022/2023

| | 2022/2023 | 2021/2022 |
|---|------------|------------|
| | Betrag | Betrag |
| Retained earnings brought forward | -23,461.41 | 9,272.18 |
| Net loss of the year | -14,498.66 | -32,733.59 |
| Retained earnings available for appropriation | -37,960.07 | -23,461.41 |

The board of directors propose the following:

| | | |
|------------------------------|------------|------------|
| Allocation to legal reserves | 0.00 | 0.00 |
| To be carried forward | -37,960.07 | -23,461.41 |
| TOTAL | -37,960.07 | -23,461.41 |